RLM.L Regulatory News (RLM)

19 November 2012

PuriCore plc

("PuriCore" or the "Company")

Interim Management Statement

Company increases sales in all business divisions

PuriCore (LSE: PURI), the water-based, clean technology company, today issues its Interim Management Statement for the period from 1 July 2012 to 16 November 2012 (which incorporates information in relation to the financial performance of the business for the third quarter being from 1 July 2012 to 30 September 2012).

Financial Highlights for the Nine Months to 30 September 2012 (unaudited)

·; Group sales up 29% (30% at constant currency) to $36.4m (2011: $28.3m)

§ Supermarket Retail (including Floral) sales up 45% to $17.7m (2011: $12.2m)

§ Endoscopy (including Scientific) sales up 11% (14% at constant currency) to $17.3m (2011: $15.6m)

§ Wound Care (including Dental) sales up 204% to $1.3m (2011 $0.4m)

·; Gross cash of $3.2m as at 30 September 2012

Operational Highlights

Food & Agriculture

·; Supermarket Retail: signed two major Sterilox Fresh and FloraFresh deals valued at $9m

·; Agriculture: reported positive results from research collaboration at Oxford University

·; Water Treatment: signed a marketing partnership agreement with Lohas Products GmbH

Health Sciences

·; Endoscopy: recurring revenues increased 5.6% (8.1% at constant currency) to $13.7m (2011: $12.7m), accounting for 77% of division sales

·; Wound Care: sales continue to grow; partnership discussions underway

Michael Ashton, Executive Chairman, said:

"PuriCore reported a strong performance in the first nine months of the year with significant sales growth in all business divisions. Throughout the Company, we continue to drive sales aggressively, focus on controlling costs, and look to develop new products and formulations that address market demands. We see significant business development and partnership opportunities to further monetise our core technology in a number of new geographies and markets including additional Health Sciences segments and Water Treatment, and continue to advance our discussions with multiple potential partners."

Business Report

Sales for the Group increased 29% (30% at constant currency) to $36.4 million in the first three quarters of 2012 (2011: $28.3 million). Gross cash at period end was $3.2 million.

Food & Agriculture

Continued robust sales in the Supermarket Retail business increased revenues 45% to $17.7 million (2011: $12.2 million). In October, the Company announced two new sales agreements. The first agreement is valued at approximately $7 million over four years with an existing customer, a top-five US supermarket retailer, to implement and use PuriCore's new formulation of FloraFresh. The second agreement is valued at approximately $2 million with a long-standing US regional supermarket customer for the capital sales of new systems to be shipped before the end of 2012. As at 30 September 2012, the Company had captured approximately 21% of the target market stores in the US and Canada.

Also in October, the Company announced further positive results from its ActiVita Agriculture programme. Testing and analysis carried out in conjunction with The University of Oxford Department of Plant Sciences continues to demonstrate ActiVita's potential as a potent broad-spectrum antifungal agent. Research is ongoing, and the Company plans to enter into discussions with potential commercialization partners.

In November, the Company announced that it signed a marketing and distribution partnership agreement with Lohas Products GmbH. PuriCore will provide technical and scientific knowledge in the development and commercialisation of new applications, and Lohas will have an exclusive license to market and distribute the applications in certain markets and territories (exclusive of the US and UK). These new potential applications include but are not limited to the use of PuriCore's technology for seafood production, water treatment in restaurants, and livestock husbandry. Collaboration on marketing plans and application development will be on-going in 2013 with revenue generation expected no later than 2014.

Health Sciences

In the Endoscopy business, strong recurring revenue streams contributed to the division's sales increase of 11% (14% at constant currency) to $17.3 million YTD (2011: $15.6 million). PuriCore increased recurring revenues by 5.6% (8.1% at constant currency), which now account for 77% of division sales. This increase was achieved by driving additional revenues from new service contracts with existing customers coming into effect, offering of private-labeled chemistries, service contract price increases for some of the legacy products, and the new catalogue of surgical consumables.

In the Wound Care business, organic and distribution revenues increased significantly by 204% to $1.3 million (2011: $0.4 million). In addition, the Company is pursuing new business development opportunities in new geographies and other Health Sciences market segments. The Company will announce details of these partnerships in due course.

Convertible Loan Notes

The Board continues its active dialogue with holders of the Company's convertible loan notes with a view to a restructuring of the loan notes and will make an announcement in due course as and when a resolution is reached.

About PuriCore

PuriCore plc (LSE: PURI) is a water-based clean technology company focused on developing and commercialising proprietary solutions that protect people from the spread of infectious pathogens without causing harm to human health or the environment. The Company's products are used in a broad range of markets that depend upon effective pathogen control including MRSA, e.Coli, and C. difficile. PuriCore is a leading full provider of all products and services required for a safe, efficient, and compliant endoscope decontamination to protect patients in UK hospitals. The Company's products are the de facto standard for food safety in leading US supermarket chains. PuriCore also offers a breakthrough wound therapy solution to treat chronic and acute wounds including diabetic ulcers and burns. PuriCore has operations in Malvern, Pennsylvania, US, and in Stafford and Clevedon, UK. To receive additional information on PuriCore, visit www.puricore.com, which does not form part of this press release.

Enquiries:

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.